Quest Diagnostics Incorporated
Financials
Valuation Metrics
Quest Diagnostics Incorporated's Market Cap is $25.68B. At end of 2025 it was $19.00B. Ranked #519 of 3,112 in US market (top 17%), #366 of 1,667 on NYSE (top 22%), #34 of 206 in Health Care Equipment & Services (top 17%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $25.68B | US#519/3,112 Sec#34/206 |
| Revenue | $11.56B | US#526/3,112 Sec#32/206 |
| Net Income | $1.06B | US#506/3,112 Sec#29/206 |
| Total Assets | $16.94B | US#682/3,112 Sec#32/206 |
| Net Assets | $7.52B | US#532/3,112 Sec#28/206 |
| Employees | 46,000 | US#183/3,112 Sec#23/206 |
| Value | ||
| P/E | 24.18x | US#1,254/3,112 Sec#37/206 |
| P/B | 3.42x | US#1,819/3,112 Sec#110/206 |
| PEG | 1.79x | US#1,015/3,112 Sec#46/206 |
| P/S | 2.22x | US#1,379/3,112 Sec#98/206 |
| EV/EBITDA | 15.66x | US#1,551/3,112 Sec#63/206 |
| FCF Yield | 4.75% | US#1,335/3,112 Sec#69/206 |
| Profitability | ||
| ROE | 14.13% | US#928/3,112 Sec#46/206 |
| ROA | 6.27% | US#830/3,112 Sec#51/206 |
| Op. Margin | 14.14% | US#1,290/3,112 Sec#51/206 |
| Revenue Growth | 10.21% | US#1,290/3,112 Sec#89/206 |
| Earnings Growth | 13.48% | US#1,075/3,112 Sec#53/206 |
| Financial Health | ||
| Debt Ratio | 121.34% | US#1,267/3,112 Sec#124/206 |
| Total Debt | $6.38B | US#554/3,112 Sec#29/206 |
| FCF | $1.22B | US#498/3,112 Sec#34/206 |
| Cash | $626M | US#932/3,112 Sec#49/206 |
| Current Ratio | 1.59x | US#1,574/3,112 Sec#142/206 |
| Net Debt/EBITDA | 2.87x | US#1,623/3,112 Sec#96/206 |
| Dividend | ||
| Div. Yield | 1.41% | US#1,118/3,112 Sec#19/206 |
| Div. Growth | 6.65% | US#688/3,112 Sec#26/206 |
| Performance | ||
| 1Y Return | 37.02% | US#1,033/3,112 Sec#67/206 |
| 1M Return | 7.55% | US#713/3,112 Sec#55/206 |
| From 52W High | -3.38% | US#385/3,112 Sec#25/206 |
| 1Y MDD | -11.94% | US#126/3,112 Sec#2/206 |
| Trading | ||
| Volume | 582,920 shares | US#1,948/3,112 Sec#143/206 |
| Trading Value | $135M | US#719/3,112 Sec#58/206 |
| Per Share | ||
| EPS | $8.94 | US#298/3,112 Sec#21/206 |
| BPS | $64.59 | US#266/3,112 Sec#19/206 |
Company Info
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.